Abstract
We present a simple and reliable method for simultaneous determination of voriconazole and its main metabolite resulting from N-oxidation (UK-121,265), in human plasma. The work-up procedure used acetonitrile and potassium salts to precipitate plasma proteins. No internal standard was used. The chromatographic system used a LiChroCART® 250-4 cartridge packed with LiChrospher® 100 RP-8 (diameter particules, 5 μm). The UV monochromatic detector was set on 260 nm. The mobile phase consisted of a 60/40 (v/v) mixture of acetonitrile and water. The flow rate was 1 mL min−1. The retention times for voriconazole and its metabolite were 8.98 and 4.02 min respectively, and total run time was 12 min. The linearity of the method was investigated from 0.31 to 10.0 mg L−1; the lowest limit of quantification was 0.30 mg L−1. Precision ranged from 2.41% to 6.32% for voriconazole and 0.80% to 11.6% for the N-oxide voriconazole metabolite. Accuracy was between 93.0% and 101% for voriconazole and 90.0% and 101% for the N-oxide voriconazole metabolite. This rapid and accurate method could be interesting to investigate metabolite/voriconazole ratio with respect to CYP2C19 genetic status and CYP3A4 activity changes.
Similar content being viewed by others
References
Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB (2003) Clin Ther 25:1321–1381
Johnson LB, Kauffman CA (2003) Clin Infect Dis 36:630–637
Denning D, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H (2002) Clin Infect Dis 34:563–571
Boyd A, Modi S, Howard S, Moore C, Keevil B, Denning D (2004) Clin Infect Dis 39:1245–1246
Eiden C, Peyrière H, Cociglio M, Djezzar S, Hansel S, Blayac JP, Hillaire-Buys D Network of the French Pharmacovigilance Centers (2007) Ann Pharmacother 41:755–763
Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N (2006) J Clin Pharmacol 46:235–243
Imhof A, Schaer D, Schwaerz U, Schanz U (2006) Swiss Med Wkly 136:739–742
Eiden C, Peyrière H, Tichit R, Cociglio M, Amedro P, Blayac JP, Margueritte G, Hillaire-Buys D (2007) J Clin Pharm Ther 32:321–324
Leveque D, Nivoix Y, Jehl F, Herbrecht R (2006) Int J Antimicrob Agents 27:274–284
Roffey S.J, Cole S, Comby P, Gibson D, Jezequel G, Nedderman A.N.R, Smith D.A, Walker D.K, Wood N (2003) Drug Metab Dispos 31:731–741
Hyland R, Jones B, Smith D (2003) Drug Metab Dispos 31:540–547
Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Nakashima M (2004) Clin Pharmacol Ther 75:587–588
Perea S, Pennick GF, Modak A, Fothergill AW, Sutton DA, Sheehan DJ, Rinaldi MG (2000) Antimicrob Agents Chemother 44:1209–1213
Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, Zembower T, Mehta J (2005) Bone Marrow Transplant 35:509–513
Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D (2006) Antimicrob Agents Chemother 50:1570–1572
Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J (2007) Cancer 109:1532–1535
Gage R, Stopher DJ (1998) Pharm Biomed Anal 17:1449–1453
Zhou L, Glickman RD, Chen N, Sponsel WE, Graybill JR, Lam KW (2002) J Chromatogr B 776:213–220
Pennick G, Clark M, Sutton DA, Rinaldi MG (2003) Antimicrob Agents Chemother 47:2348–2350
Péhourcq F, Jarry C, Bannawarth B (2004) Biomed Chromatogr 18:719–722
Keevil BG, Newman S, Lockhart S, Howard SJ, Moore CB, Denning DW (2004) Ther Drug Monit 26:650–657
Egle H, Trittle R, Konig A, Kummerer KJ (2005) J Chromatogr B Analyt Technol Biomed Life Sci 814:361–367
Vogeser M, Schiel X, Spöhrer U (2005) Clin Chem Lab Med 43:730–734
Khoschsorur G.A, Fruehwirth F, Zelzer S (2005) Antimicrob Agents Chemother 49:3569–3571
Wenk M, Droll A, Krähenbühl SJ (2006) J Chromatogr B Analyt Technol Biomed Life Sci 832:313–316
Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien VJ (2007) J Chromatogr B Analyt Technol Biomed Life Sci 852:223–228
Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Decosterd LA, Buclin T, Majcherczyk PA, Sanglard D, Marchetti O (2007) Antimicrob Agents Chemother 51:137–143
Araujo BV, Conrado DJ, Palma EC, Costa TD (2007) J Pharm Biomed Anal 44:985–990
US Food Drug Administration. Guidance for industry (2001). http://www.fda.gov/cder/guidance/4252fnl.htm. Accessed May 2004
United States Pharmacopoeia XXXIII, The United States Pharmaopeia Convention, Rockeville, MD, 2003, p 2439
Blanchard J (1981) J Chromatogr B 226:455–460
Ng TKC, Chan RCY, Adeyemi-Doro FAB, Cheung SW, Cheng AFB (1996) J Antimicrob Chemother 37:465–472
Cociglio M, Brandissou S, Alric R, Bressolle F (1996) J Chromatogr B 686:11–17
Mikus G, Schöwel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T, Haefeli W (2006) Clin Pharmacol Ther 80:126–135
Andes D, Marchillo K, Stamstad T, Conklin R (2003) Antimicrob Agents Chemother 47:3165–3169
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eiden, C., Mathieu, O., Peyrière, H. et al. Simultaneous Quantification of Voriconazole and Its N-Oxide Metabolite in Human Plasma by an Easy and Rapid Isocratic LC Method with UV Detection. Chroma 67, 275–280 (2008). https://doi.org/10.1365/s10337-007-0508-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1365/s10337-007-0508-z